Archive for the 'Type of Assessment:' Category
January 6th, 2009. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas
0004). Our study indicated that BMP3b and BMP6 genes were suppressed by DNA methylation and methylation of BMP3b is significantly frequent in Japanese MPMs, suggesting its pathogenic role and the ethnic difference in MPMs.
January 6th, 2009. Telomerase Activity in Effusions: A Comparison Between Telomere Repeat Amplification Protocol In Situ and Conventional Telomere Repeat Amplification Protocol Assay
Conclusions: The TRAP in situ results correlated to final diagnoses, whereas the cell lysate–based TRAP assay did not differentiate between malignant and benign cases. The varying proportions of positive cells and the variation in fluorescence intensity in the TRAP in situ slides explained some of the discrepancies. The problems encountered with TRAP performed on cell lysates are partly overcome using TRAP in situ.
January 6th, 2009. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
In conclusion, insulin-like growth factor-II and insulin-like growth factor binding protein-3 are more frequently expressed in metastatic carcinomas compared to mesothelioma in effusions but are less specific than currently used markers. Insulin-like growth factor-II and insulin-like growth factor binding protein-3 may be novel prognostic markers in metastatic ovarian carcinoma.
January 2nd, 2009. New diagnostic and molecular characteristics of malignant mesothelioma
In addition to the improved tools available for serosal cancer diagnosis, knowledge regarding the biology of malignant mesothelioma has been accumulating in recent years. This review presents current data regarding the diagnostic and biological aspects of malignant mesothelioma.
January 2nd, 2009. Epigenetic Profiles Distinguish Pleural Mesothelioma from Normal Pleura and Predict Lung Asbestos Burden and Clinical Outcome
We have added to the growing body of evidence that cellular epigenetic dysregulation is a critical mode of action for asbestos in the induction of pleural mesothelioma. Importantly, these findings hold great promise for using epigenetic profiling in the diagnosis and prognosis of human cancers.
January 2nd, 2009. Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Cancer
Conclusions: Pemetrexed with vitamin supplementation was safe and well tolerated at higher doses than the currently established 500 mg/m2 + 75 mg/m2 cisplatin. Based on this study, the recommended dose would be 800 mg/m2 pemetrexed + 75 mg/m2 cisplatin. However, recent studies showed a lack of improved efficacy for 900 or 1,000 mg/m2 single-agent pemetrexed versus 500 mg/m2 and a lack of PK/pharmacodynamic exposure-response relationship for the pemetrexed/cisplatin combination across pemetrexed exposures corresponding to this dose range. Based on currently available evidence, we recommend retaining the established dose.
January 2nd, 2009. A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy
Conclusions: Electrocautery biopsy using the IT knife during semirigid pleuroscopy has great potential for diagnosing smooth abnormal pleura which are difficult to biopsy with SFF.
December 25th, 2008. Proteome analysis of bronchoalveolar lavage in individuals from Metsovo, nonoccupationally exposed to asbestos
Proteomic analysis (2D-electrophoresis/Mass Spectrometry) of BAL in Metsovites nonoccupationally exposed to asbestos revealed increased albumin fragments, alpha1-antitrypsin, S100-A9 and HSP27, suggesting ongoing inflammation. In those without pleural calcifications, increased expression of acid ceramidase, glutathione-S-transferase and presence of calcyphosin, all involved in cell cycle regulation and death as well as in the detoxification of mutagenic and toxic agents, lend further support to our thesis of possible "protection against neoplasia" in Metsovites with pleural calcifications.
December 25th, 2008. Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy
Conclusion: Cytoreductive surgery combined with HIPEC may improve the length of survival for patients with diffuse malignant peritoneal mesothelioma; such patients should be treated in specialized centers.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 25th, 2008. Malignant pleural effusion as the presenting site of cancer: comparison with metastatic pleural effusions from known cancers
Conclusion: Pleural effusions as the presenting site of cancer account for 41% of all malignant pleural effusions. Their causes are mainly lung cancer in men and lung and ovarian cancers in women.
December 23rd, 2008. Advantages of multidetector-row CT with multiplanar reformation in guiding percutaneous lung biopsies
Conclusions: MDCT MPR images allowed sampling of pulmonary lesions until now considered unreachable with axial MDCT guidance because of overlying bony structures (ribs, sternum and scapulae) or critical location (hilar-mediastinal, proximity to the heart or large vessels). Compared with the conventional procedure, the use of MPR images does not increase the rate of pneumothorax or the procedure time.
December 23rd, 2008. D2-40 Immunohistochemistry-So Far!
More recently, D2-40 immunoexpression has been reported in primary adrenal cortical tumors, schwannomas, and adnexal tumors of the skin. This brief review provides an update on the ever-expanding proposed applications of D2-40 immunohistochemistry in surgical pathology.
December 23rd, 2008. Malignant mesothelioma
Compensation issues must also be considered. Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
Posted in Benign, CT or CAT scan, Causation, Diagnosis & Differentiation, Environmental Asbestos Exposure, Full Archive, General, Occupational Asbestos Exposure, Pericardial, Peritoneal (Abdominal Mesothelioma), Pleural, Survival, Symptoms & Symptom Management, Treatment, Trimodality Therapy, Tunica Vaginalis Testis, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 20th, 2008. A review of mesothelioma information on the World Wide Web
Conclusions: There is marked variation in the quality, integrity, and currency of the information in educational websites for mesothelioma patients. Google ranking has shown a weak but significant positive correlation to the quality of medical information relating to mesothelioma.
December 20th, 2008. Vitamin D-mediated hypercalcemia and Cushing syndrome as manifestations of malignant pleural mesothelioma
Conclusion: These findings support the evidence for a paracrine role of vitamin D in the resistance of the human host to antigen.
December 20th, 2008. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
Conclusions: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma. Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.
December 19th, 2008. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
Conclusion: Pemetrexed-pretreated patients with progressive MPM may benefit from a consecutive chemotherapy with oxaliplatin and gemcitabine without significant toxicity.
December 18th, 2008. Spontaneously immortalized mouse mesothelial cells display characteristics of malignant transformation
Conclusion: These findings have implications for interpretation of in vitro transformation studies, demonstrating broad similarity between spontaneous and induced genetic changes.
December 18th, 2008. Redo medical thoracoscopy is feasible in patients with pleural diseases – a series
46), as well as no complications directly attributed to the repeat pleural endoscopy. Repeat medical thoracoscopy is technically feasible in patients with pleural disease without an associated increased morbidity and mortality.
December 18th, 2008. Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population
Although the hazards of asbestos are well known in developed countries, awareness of its adverse health effects is less in other parts of the world, particularly when exposure occurs in non-occupational settings. Experience of asbestos use and its adverse heath effects in developed countries such as Australia have resulted in development of expertise in the diagnosis and treatment of asbestos-related diseases as well as in screening and this can be used to help developing countries facing the issue of asbestos exposure.
|
|  |
